Literature DB >> 20211558

Genetic advances in glioma: susceptibility genes and networks.

Yanhong Liu1, Sanjay Shete, Fay Hosking, Lindsay Robertson, Richard Houlston, Melissa Bondy.   

Abstract

Recent advances in human genome studies have opened new avenues for the identification of susceptibility genes for many complex genetic disorders, especially in the field of rare cancers such as glioma. To date, eight glioma susceptibility loci have been identified by candidate gene-association studies: PRKDC G6721T, XRCC1 W399R, PARP1 A762V, MGMT F84L, ERCC1 A8092C, ERCC2 Q751K, EGF +61 A/G, and IL13 R110G. Five loci have been identified by genome-wide association studies: TERT rs2736100, CCDC26 rs4295627, CDKN2A-CDKN2B rs4977756, PHLDB1 rs498872, and RTEL1 rs6010620. Using the Ingenuity Pathway Analysis tool, we investigated whether these 13 susceptibility genes are biologically related. Our data provide not only networks for understanding the biological properties of gliomagenesis but also useful pathway maps for future understanding of disease.

Entities:  

Mesh:

Year:  2010        PMID: 20211558      PMCID: PMC2885452          DOI: 10.1016/j.gde.2010.02.001

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  39 in total

1.  Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.

Authors:  J Fuxe; G Akusjärvi; H M Goike; G Roos; V P Collins; R F Pettersson
Journal:  Cell Growth Differ       Date:  2000-07

2.  Microsatellite instability, PTEN and p53 germline mutations in glioma families.

Authors:  B Malmer; H Grönberg; U Andersson; B A Jonsson; R Henriksson
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

3.  Germline mutations of p53 but not p16/CDKN2 or PTEN/MMAC1 tumor suppressor genes predispose to gliomas. The ANOCEF Group. Association des NeuroOncologues d'Expression Française.

Authors:  X P Zhou; M Sanson; K Hoang-Xuan; E Robin; L Taillandier; J He; K Mokhtari; P Cornu; J Y Delattre; G Thomas; R Hamelin
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

4.  A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.

Authors:  J A Randerson-Moor; M Harland; S Williams; D Cuthbert-Heavens; E Sheridan; J Aveyard; K Sibley; L Whitaker; M Knowles; J N Bishop; D T Bishop
Journal:  Hum Mol Genet       Date:  2001-01-01       Impact factor: 6.150

5.  Association of an ERCC1 polymorphism with adult-onset glioma.

Authors:  P Chen; J Wiencke; K Aldape; A Kesler-Diaz; R Miike; K Kelsey; M Lee; J Liu; M Wrensch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-08       Impact factor: 4.254

6.  Analysis of p53 tumor suppressor gene in families with multiple glioma patients.

Authors:  N Paunu; K Syrjäkoski; R Sankila; K O Simola; P Helén; M Niemelä; M Matikainen; J Isola; H Haapasalo
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

7.  Gamma-radiation sensitivity and risk of glioma.

Authors:  M L Bondy; L E Wang; R El-Zein; M de Andrade; M S Selvan; J M Bruner; V A Levin; W K Alfred Yung; P Adatto; Q Wei
Journal:  J Natl Cancer Inst       Date:  2001-10-17       Impact factor: 13.506

8.  DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas.

Authors:  Martha J Felini; Andrew F Olshan; Jane C Schroeder; Kari E North; Susan E Carozza; Karl T Kelsey; Mei Liu; Terri Rice; John K Wiencke; Margaret R Wrensch
Journal:  Neuroepidemiology       Date:  2007-09-24       Impact factor: 3.282

9.  TERT regulates cell survival independent of telomerase enzymatic activity.

Authors:  Ying Cao; He Li; Siddhartha Deb; Jun-Ping Liu
Journal:  Oncogene       Date:  2002-05-09       Impact factor: 9.867

10.  A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage.

Authors:  Sherif F El-Khamisy; Mitsuko Masutani; Hiroshi Suzuki; Keith W Caldecott
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

View more
  33 in total

1.  Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis.

Authors:  Wei-Zhong Xiao; Dong-Hua Han; Fei Wang; Yong-Qian Wang; You-Hou Zhu; Yi-Fang Wu; Ning-Tao Liu; Ji-Yong Sun
Journal:  Tumour Biol       Date:  2014-04-08

2.  Association of single-nucleotide polymorphisms in ERCC1 and ERCC2 with glioma risk.

Authors:  Lei Hui; Shuangzhu Yue; Guojun Gao; Haigang Chang; Xiangsheng Li
Journal:  Tumour Biol       Date:  2014-05-01

3.  Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.

Authors:  Sabine Spiegl-Kreinecker; Daniela Lötsch; Bahil Ghanim; Christine Pirker; Thomas Mohr; Magdalena Laaber; Serge Weis; Alfred Olschowski; Gerald Webersinke; Josef Pichler; Walter Berger
Journal:  Neuro Oncol       Date:  2015-02-13       Impact factor: 12.300

Review 4.  DNA repair gene ERCC1 polymorphisms and glioma susceptibility among Chinese population: a meta-analysis.

Authors:  Chunming Jiang; Fang Shen; Jianmin Du; Xiaohua Wang; Jin Su; Zhanli Liu; Xianmei Huang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

5.  Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma.

Authors:  Yanhong Liu; Beatrice S Melin; Preetha Rajaraman; Zhaoming Wang; Martha Linet; Sanjay Shete; Christopher I Amos; Ching C Lau; Michael E Scheurer; Spiridon Tsavachidis; Georgina N Armstrong; Richard S Houlston; Fay J Hosking; Elizabeth B Claus; Jill Barnholtz-Sloan; Rose Lai; Dora Il'yasova; Joellen Schildkraut; Siegal Sadetzki; Christoffer Johansen; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Daniel LaChance; Nicholas A Vick; Margaret Wrensch; Faith Davis; Bridget J McCarthy; Ulrika Andersson; Patricia A Thompson; Stephen Chanock; Melissa L Bondy
Journal:  Hum Genet       Date:  2012-06-12       Impact factor: 4.132

6.  A functional polymorphism in XRCC1 is associated with glioma risk: evidence from a meta-analysis.

Authors:  Xiangtai Wei; Duo Chen; Tao Lv
Journal:  Mol Biol Rep       Date:  2012-10-25       Impact factor: 2.316

7.  Comprehensive assessment of the association of ERCC2 Lys751Gln polymorphism with susceptibility to cutaneous melanoma.

Authors:  Yuhao Dong; Le Zhuang; Weiyuan Ma
Journal:  Tumour Biol       Date:  2013-02-03

8.  Associations between three XRCC1 polymorphisms and glioma risk: a meta-analysis.

Authors:  Haijun Zhang; Hang Liu; Jennifer L Knauss
Journal:  Tumour Biol       Date:  2013-05-29

9.  Analysis of difference of association between polymorphisms in the XRCC5, RPA3 and RTEL1 genes and glioma, astrocytoma and glioblastoma.

Authors:  Tianbo Jin; Yuan Wang; Gang Li; Shuli Du; Hua Yang; Tingting Geng; Peng Hou; Yongkuan Gong
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

10.  Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma.

Authors:  Zengjin Liu; Huamin Han; Xin He; Shouwei Li; Chenxing Wu; Chunjiang Yu; Shengdian Wang
Journal:  Oncol Lett       Date:  2016-01-26       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.